Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fostemsavir→

Fostemsavir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
864953-29-7
Molecular formula
C25H26N7O8P
Molecular weight
583.5 g/mol
Drug class
HIV-1 attachment inhibitorprodrug of temsavir
Mechanism of action
Fostemsavir is hydrolysed to temsavir, which binds the gp120 subunit of the HIV-1 envelope glycoprotein and prevents viral attachment to the CD4 receptor, blocking an early step in viral entry.
Indications / reported uses
  • Treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 for whom the current antiretroviral regimen is failing due to resistance, intolerance or safety considerations, in combination with other antiretroviral agents

Sources: US DailyMed — RUKOBIA (fostemsavir) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fostemsavir Environmental Risk Assessment (ERA) (the Fostemsavir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.